Shared on 01 Nov 25
Fair value Increased 7.14%Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.
Shared on 18 Oct 25
Fair value Increased 7.69%EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.
Shared on 04 Oct 25
Fair value Increased 6.12%EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.
Shared on 07 Aug 25
Fair value Increased 18%EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.
Shared on 01 May 25
Fair value Increased 18%ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
Shared on 24 Apr 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 15%ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
AnalystConsensusTarget has decreased future PE multiple from 49.5x to 43.3x and decreased shares outstanding growth rate from 0.0% to 0.0%.